Fisher & Paykel Healthcare (ASX:FPH, NZE:FPH) said the 10% US tariffs on products manufactured in New Zealand will not significantly impact its fiscal 2025 net profit but are expected to drive higher costs in fiscal 2026, according to a Thursday filing with the Australian and New Zealand bourses.
About 55% of its production is based in New Zealand, with around 40% of its US volumes supplied from there, the filing added, the filing said.
Shares of the company fell almost 5% in New Zealand in recent Thursday trade.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。